Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BF.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.5.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.59NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BF.15NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BQ.1.15NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CA.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CP.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.3.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
ED.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
CM.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-630.996US
BQ.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
CA.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BN.1.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BQ.1.28NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
DG.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BA.5.2.56NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-18009.5US
KP.2.13NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XDP.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HN.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
KL.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.24.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GK.2.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.1.5.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EE.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DB.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BW.1.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.22NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BE.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KB.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HF.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BG.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.42.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.517NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.427 (Epsilon)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.429 (Epsilon)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.166NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.4.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.7.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.99.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-22381.5US
KT.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23154.8US
JC.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.334NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.359NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.302NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.222NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.434NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.467NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.110.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used